Skip to main content

Table 1 Cellular Therapies for Glioma Patients

From: Cellular and vaccine therapeutic approaches for gliomas

Center/Investigator

Therapy/Protocol

Phase - Enrollment

ND, P, R*

WHO Grade***

Clinicaltrials.gov identifier

References

City of Hope, Duarte, CA/B Badie

Allogeneic T Cells modified with chimeric IL-13α2 - TCRζ

I - 10

R, P

III or IV

NCT01082926

Kahlon et al [9]

Baylor College of Medicine, Houston, TX/N Ahmed

Autologous CMV specific CTL genetically modified to target Her2

I/II - 18

ND

IV

NCT01109095

Ahmed et al [18]

Penn State University, Hershey, PA/K Lucas

Allogeneic, CMV specific CTL

I/II - 10

R

IV

NCT00990496

Bao et al [20, 72]

UCLA, Los Angeles, CA/L Liau

Alloreactive CTL and IL-2

1 - 15

R

III

NCT01144247

Kruse & Rubinstein [21]

Hoag Cancer Center, Newport Beach, CA/R Dillman

Autologous LAK Cells

II - 80

ND

IV

NCT00814593

Dillman et al [22, 73]

  1. * ND, Newly Diagnosed; P, Persistent; R, Recurrent
  2. ** World Health Organization (WHO) Grade III: AA, AODG; Grade IV: GBM